

**National Institute for Health and Clinical Excellence**

Amantadine, oseltamivir and zanamivir for the treatment of influenza

**Comments on the Assessment Report**

**Stakeholder Comments**

Please use this form for submitting your comments to the Institute.

1. Please put each new comment in a new row.
2. Please do not paste other tables into this table, as your comments could get lost – type directly into this table.
3. Please insert the **section number** in the 2<sup>nd</sup> column. If your comment relates to the document as a whole, please put **'general'** in this column. **Please refer to section numbers and not page numbers.**

	<b>Name:</b>	<b>Royal College of Paediatrics and Child Health</b>
	<b>Stakeholder Organisation:</b>	<b>Royal College of Paediatrics and Child Health</b> With thanks to: [REDACTED], Consultant Paediatrician [REDACTED], Consultant in Paediatric Intensive Care
<b>Comment No.</b>	<b>Section number</b> <small>Indicate <b>section number</b> or <b>'general'</b> if your comment relates to the whole document</small>	<b>Comments</b>  Please insert each new comment in a new row.
1	General	This is a detailed document addressing an issue about which there is much uncertainty, in a common clinical diagnosis. The document could be made more user-friendly by outlining any take-home messages e.g. use in high risk groups? What are high risk groups? Which antiviral to use?  These issues have been dealt with in detail in the body of the text but are not easy for a busy clinician to access quickly.
2	General	This paper highlights the paucity of data in children (particularly at risk children) and the complete lack of data in infants. A major effort should be made to address these issues and this should be highlighted in the report. In addition, the lack of a suitable formulation for patients (infants, children and adults) unable to take those available, make them particularly vulnerable.
3		
4		

Please add extra rows as needed